Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Daxor Corp (DXR)

Daxor Corp (DXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,042
  • Shares Outstanding, K 4,837
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -7,190 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta 0.00
  • Price/Sales 19.00
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.11 +9.47%
on 12/09/25
13.53 -2.00%
on 11/25/25
+0.07 (+0.51%)
since 11/21/25
3-Month
11.35 +16.83%
on 10/27/25
14.15 -6.29%
on 11/20/25
+1.11 (+9.12%)
since 09/23/25
52-Week
6.55 +102.44%
on 02/11/25
14.15 -6.29%
on 11/20/25
+4.96 (+59.76%)
since 12/23/24

Most Recent Stories

More News
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR),...

DXR : 13.26 (+5.07%)
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the...

DXR : 13.26 (+5.07%)
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom...

DXR : 13.26 (+5.07%)
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor...

DXR : 13.26 (+5.07%)
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR),  the global...

DXR : 13.26 (+5.07%)
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. ...

DXR : 13.26 (+5.07%)
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh...

DXR : 13.26 (+5.07%)
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available

The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA â„¢ . Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation...

DXR : 13.26 (+5.07%)
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood...

DXR : 13.26 (+5.07%)
Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions

Continued Integration of Daxor’s ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global...

DXR : 13.26 (+5.07%)

Business Summary

Daxor Corporation is a medical device manufacturing corporation with additional biotech services.

See More

Key Turning Points

3rd Resistance Point 12.78
2nd Resistance Point 12.70
1st Resistance Point 12.66
Last Price 13.26
1st Support Level 12.54
2nd Support Level 12.46
3rd Support Level 12.42

See More

52-Week High 14.15
Last Price 13.26
Fibonacci 61.8% 11.25
Fibonacci 50% 10.35
Fibonacci 38.2% 9.45
52-Week Low 6.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar